India to Mauritius: Acarbose Export Trade Route

To import Acarbose formulations into Mauritius, the following approvals and registrations are mandatory:

• Product Registration: All pharmaceutical products must be registered with the National DRA before importation. The registration dossier should be compiled in the Common Technical Document (CTD) format, encompassing modules on quality, safety, and efficacy.

• Dossier Submission: The CTD dossier must include comprehensive data on the product's composition, manufacturing process, quality control measures, and clinical studies.

• Approval Timelines: The National DRA typically processes registration applications within a specified timeframe, which may vary based on the completeness of the submission and the complexity of the product.

• Registration Fees: Applicants are required to pay a non-refundable application fee as specified in the National DRA's fee schedule.

• GMP Inspection Requirements: The National DRA mandates Good Manufacturing Practice (GMP) compliance for all manufacturing facilities. Indian manufacturers exporting to Mauritius must provide a valid GMP certificate issued by the relevant Indian authority. Additionally, the National DRA may conduct its own inspections or require inspection reports from recognized international bodies to ensure compliance with GMP standards.

Indian exporters of Acarbose formulations must adhere to the following GMP certifications and standards to supply products to Mauritius:

• GMP Certification: Manufacturers must hold a valid GMP certificate, such as the WHO-GMP certification, which attests to compliance with international manufacturing standards.

• Approved Facilities: Only manufacturing facilities that have been inspected and approved by the National DRA or recognized international regulatory bodies are authorized to export to Mauritius.

• Recent Inspections and Regulatory Actions: The National DRA maintains records of inspections and any regulatory actions taken against pharmaceutical companies. Manufacturers are advised to stay informed about any updates or changes in compliance requirements to ensure uninterrupted market access.

In the past 18 months, several regulatory changes and policy shifts have impacted Indian pharmaceutical exports to Mauritius:

• Implementation of ASEAN CTD Format: As of January 2025, the National DRA has adopted the ASEAN Common Technical Dossier (ACTD) format for product registration. This harmonization aims to streamline the registration process and align with regional standards.

• Mutual Recognition Agreements (MRAs): In March 2025, Mauritius entered into an MRA with select ASEAN countries, facilitating easier market access for pharmaceutical products that have been approved in these member states.

• Revised GMP Inspection Protocols: Effective July 2025, the National DRA updated its GMP inspection protocols to include risk-based assessments, focusing on high-risk products and manufacturing processes.

These developments underscore the importance for Indian exporters to stay abreast of regulatory changes and ensure compliance with the latest standards to maintain market access in Mauritius.

Acarbose is an alpha-glucosidase inhibitor used in the management of type 2 diabetes by slowing carbohydrate digestion, thereby reducing postprandial blood glucose levels. The global acarbose market is projected to grow at a compound annual growth rate (CAGR) of 2.8% from 2025 to 2035.

In Mauritius, the prevalence of diabetes is a significant health concern, with approximately 22% of the adult population affected as of 2024. This high prevalence drives the demand for effective diabetes management medications, including acarbose formulations. The country's healthcare system provides universal health coverage, ensuring that residents have access to necessary treatments. While Mauritius imports a substantial portion of its pharmaceutical products, there is also a growing domestic pharmaceutical manufacturing sector that contributes to meeting local demand.

Mauritius maintains a 0% import duty on pharmaceutical products classified under HS code 30049099, which includes acarbose formulations. This policy is designed to ensure the affordability and availability of essential medicines. Additionally, Mauritius is a member of the Common Market for Eastern and Southern Africa (COMESA), which facilitates preferential trade agreements among member countries. However, specific details regarding any free trade agreements (FTAs) between India and Mauritius affecting pharmaceutical tariffs are not readily available. There are no known anti-dumping duties imposed on pharmaceutical imports under this HS code.

India is a key supplier of acarbose formulations to Mauritius, accounting for 0.6% of India's total acarbose formulation exports, valued at $6.8 million. The primary exporters from India include HEXA HEALTHCARE PRIVATE LIMITED and SAVA HEALTHCARE LIMITED. The main importers in Mauritius are REGENCY PHARMA LIMITED and WAREHOUSE NO.1 BPML FREEPORT ZONE. The majority of shipments are routed through Indian ports such as SAHAR AIR and Bombay Air Cargo.

While India is a significant supplier, Mauritius also imports pharmaceutical products from other countries, including those in the European Union and China. However, specific data on the market share of these countries in Mauritius's acarbose imports is not readily available. India's competitive pricing, coupled with the 0% import duty, positions it favorably in the Mauritian market compared to other suppliers.

India is a leading global hub for generic pharmaceutical production, accounting for approximately 20% of the global supply by volume. This extensive manufacturing capability extends to finished dosage forms containing Acarbose, a medication widely used in diabetes management. The country's cost-effective production processes, driven by economies of scale and a competitive labor market, enable the production of Acarbose formulations at prices lower than many other regions. As of October 2023, India maintained its position as the top country with FDA-registered generic facilities, with 376 facilities registered for fiscal year 2024, including 134 dedicated to finished dosage forms. This robust infrastructure ensures consistent quality and compliance with international standards, making India a preferred source for Acarbose formulations.

When comparing Acarbose formulation exports, India offers a compelling balance of cost and quality. Chinese manufacturers, while producing a significant portion of active pharmaceutical ingredients (APIs), have a limited presence in the finished dosage form market, with only about 5-7% of their pharmaceutical exports being finished products. Additionally, concerns have been raised regarding the quality of some Chinese generic formulations. European Union (EU) manufacturers are renowned for high-quality branded generics but often come with higher price points due to stringent regulatory requirements and higher production costs. In Mauritius, Indian Acarbose formulations are well-accepted, meeting local regulatory standards and offering a reliable supply chain. While specific pricing data varies, Indian formulations generally provide a cost advantage over EU products without compromising on quality.

The India-Mauritius supply chain for Acarbose formulations has demonstrated reliability, supported by India's substantial manufacturing capacity. Indian facilities are equipped with advanced packaging and cold chain capabilities, ensuring the stability and efficacy of Acarbose formulations during transit. Recent inspections, such as the U.S. FDA's routine GMP inspection at Dr. Reddy's Laboratories' formulations manufacturing facilities in May 2024, resulted in a classification of Voluntary Action Indicated (VAI), indicating compliance with regulatory standards. Leading manufacturers continue to expand their capacities; for instance, Granules India's new facility at Genome Valley, Hyderabad, received U.S. FDA approval in August 2025, adding significant formulation capacity. These developments underscore the robustness and reliability of India's pharmaceutical manufacturing sector.

For Mauritius buyers sourcing Acarbose formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Acarbose formulations.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Familiarize yourself with common payment terms in India-Mauritius pharmaceutical trade, such as Letters of Credit (LC) or advance payments, to facilitate smooth transactions.

• Supplier Qualification Process: Implement a thorough qualification process, including audits of manufacturing facilities, verification of regulatory certifications (e.g., WHO-GMP, FDA approvals), and assessment of quality control systems.

• Regulatory Compliance: Ensure that selected suppliers comply with both Indian and Mauritian regulatory requirements to avoid potential legal and operational issues.

By adopting these strategies, Mauritius buyers can establish a reliable and cost-effective supply chain for Acarbose formulations from India.

By adhering to this comprehensive approach, Mauritius buyers can ensure the selection of reliable Indian Acarbose suppliers, maintaining high standards of product quality and regulatory compliance.